注射用尤瑞克林治疗急性脑梗死临床观察

目的评价尤瑞克林治疗急性脑梗死的疗效和安全性．方法急性脑梗死患者41例，给予0．9％生理盐水100mL＋尤瑞克林0．15 PNA静脉滴注，每天1～2次，连续治疗5～7d；治疗期间同时给予抗血小板制剂以及其它常规治疗．治疗前后，对比美国国立卫生研究院脑卒中量表（NIHSS）和改良Rankin Scale（MRS）量表来评价临床疗效，监测血常规、尿常规、肝肾功能、空腹血糖、血脂．对不良反应作详细观察记录．结果治疗后，NIHSS和MRS均有明显改善（P〈0．05），总有效率达85．4％，死亡率为0，未见明显不良反应．结论尤瑞克林不失为治疗急性脑梗死的一种安全、有效的药物，有良好的临床应用前景．

The Clinical Observation of Urinary Kallidinogenase in Treatment of Acute Cerebral Infarction

Objective To evaluate the efficacy and safety of Urinary Kallidinogenase in treatment of patients with acute cerebral infarction. Methods 41patients diagnosed of acute cerebral infarction were treated with Kallidinogenase injection. These patients were evaluated by NIHSS and Rankin scale （MRS） at day 5 - 7 after starting the therapy. Results A significant improvement in NIHSS and MRS scores of these patients was noted. 85.4% of them obtained satisfactory improvement. Conclusion Kallidinogenase injection is safe and effective on the improvement of cerebral functions in patients with acute cerebral infarction.